TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06369571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg daily by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of dietary fat composition
Description: Replace 10% of saturated fat intake with polyunsaturated fat
Study: NCT05580718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT
Description: * Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle.
Study: NCT05049902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.
Study: NCT05813743

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3 dimensional ultrasound
Description: Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
Study: NCT06498050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of Brolucizumab 6 mg in study eye
Description: After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
Study: NCT05049902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.
Study: NCT05622591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELU001
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Study: NCT05049902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.
Study: NCT06442384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco and non-tobacco e-cigarettes
Description: Participants with no e-cigarette restrictions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco only e-cigarettes
Description: Participants restricted to tobacco flavored e-cigarettes only.
Study: NCT05352074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subtotal colectomy with cecal-rectal anastomosis
Description: The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total colectomy with ileorectal anastomosis
Description: After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
Study: NCT06462768

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
Study: NCT05065099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)
Description: Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
Study: NCT05283291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directed Imagery Technique
Description: The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music.
Study: NCT06152211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choir
Description: A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Music Listening
Description: A weekly collective music listening, 2 hours each for 16 weeks.
Study: NCT06548451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented reality guided localization
Description: In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
Study: NCT06124846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB-Abst
Description: incentivized, biochemically verified abstinence via contingency management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB-Mon
Description: monitoring with no required abstinence
Study: NCT05281328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029
Description: SC injection using a pre-filled pen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029
Description: SC injection using a pre-filled pen
Study: NCT05005546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga will be applied to mothers in the yoga group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter Yoga will be applied to mothers in the yoga group
Study: NCT05281328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection using a pre-filled pen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection using a pre-filled pen
Study: NCT06537531

Intervention type: OTHER
Intervention: Compare VCI scale
Description: Compare VCI scale
Study: NCT05217537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Injection [Nuzyra]
Description: Single dose of 100 mg omadacycline IV in 100 mL of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Injection [Nuzyra]
Description: Single dose of 100 mg omadacycline IV in 100 mL of normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Oral Tablet
Description: Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Oral Tablet
Description: Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
Study: NCT05983653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis without PRP
Description: 150 ml arthrocentesis without PRP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis with PRP
Description: 150 ml arthrocentesis with PRP
Study: NCT04379011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Escalating brivaracetam dose to 150 mg twice daily for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 3 months
Study: NCT04833166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMAC D-blade videolaryngoscope with full or partial glottic view
Description: Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMAC D-blade videolaryngoscope with full or partial glottic view
Description: Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
Study: NCT06081166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib
Description: obicetrapib 10 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib
Description: obicetrapib 10 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Rosuvastatin 40 mg
Study: NCT06227780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Auditory Entrainment
Description: Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alpha Auditory Entrainment
Description: Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers
Study: NCT04294290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC infusion
Description: This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
Study: NCT06227780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Auditory Entrainment
Description: Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers
Study: NCT04863950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine Hydrochloride
Description: For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days.
Study: NCT06535906

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo kinesio taping
Description: 5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual lymph drainage
Description: Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo manual lymph drainage
Description: Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
Study: NCT04701268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: Hemiverse
Description: Implantation of the hemiverse shoulder prothesis
Study: NCT04916847

Intervention type: OTHER
Intervention: blood collection
Description: Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay.
Study: NCT06526507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation strategy package
Description: Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
Study: NCT05435573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 mL of ringer's acetate solution
Description: 1000 mL of ringer's acetate solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)
Description: 500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
Study: NCT06205290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liso-cel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idelalisib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study: NCT06463535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: SRP + OMEGA 3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP alone
Description: Scaling and root planning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP alone
Description: Scaling and root planning
Study: NCT05754086

Intervention type: BEHAVIORAL
Intervention: Clear Speech
Description: This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss.

Intervention type: BEHAVIORAL
Intervention: Clear Speech
Description: This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss.

Intervention type: BEHAVIORAL
Intervention: Less Clear Speech
Description: This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear.

Intervention type: BEHAVIORAL
Intervention: Less Clear Speech
Description: This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear.
Study: NCT06028061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant-free Quadratus lumborum block
Description: Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block III with Adjuvant
Description: The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
Study: NCT06434207

Intervention type: OTHER
Intervention: Collecting discarded blood samples
Description: Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
Study: NCT04901455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV
Description: Standard dose of LAIV administered by a licensed health care providers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV
Description: Standard dose of LAIV administered by a licensed health care providers.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV
Description: Standard dose of LAIV administered by a licensed health care providers.
Study: NCT04899063

Intervention type: DEVICE
Group type: OTHER
Intervention: ELIOS Procedure
Description: Treatment with the ELIOS System